Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOCRATES Goes Spain and Turkey

Published: Thursday, May 10, 2012
Last Updated: Wednesday, May 09, 2012
Bookmark and Share
Austrian diagnostic expert in personalized medicine continues to expand its European distribution network.

BIOCRATES Life Sciences AG has announced that it has entered into a distribution and co-marketing agreement with MATERLAB in Spain and ONKOGEN Diagnostik in Turkey to bring its latest metabolomic product, SteroIDQ® Kit, to the markets of their respective countries.

SteroIDQ® kit, a CE-IVD ready-to-use kit, was successfully launched in Germany, Austria, and Switzerland earlier this year, and is the first of a new generation of steroid hormone kits, enabling the most comprehensive simultaneous analysis of a steroid panel yet available.

Analysis is based on tandem mass spectrometry (LC-MS/MS), which meets the most stringent quality control criteria for routine diagnostics and ensures extraordinary analytical sensitivity and selectivity.

Under the terms of the agreement, MATERLAB and ONKOGEN Diagnostik are granted rights for distribution and sale of all BIOCRATES products, its metabolomic research-use-only kits (AbsoluteIDQ® p150 Kit, AbsoluteIDQ® p180 Kit, MetaDisIDQ® Kit) as well as its novel CE-IVD SteroIDQ® Kit.

“We are happy to have found such competent and highly successful partners to support us in extending the BIOCRATES presence into the Spanish and Turkish market respectively.” says Elgar Schnegg, CEO of BIOCRATES.

Schnegg continued, “With the extensive distribution network of both MATERLAB and ONKOGEN Diagnostik, coupled with their drive and enthusiasm in bringing together cutting-edge products from prime biotech and microbiology manufacturers worldwide to serve laboratories across Spain and Turkey make them ideal partners in our endeavor of further expanding the European distribution network of BIOCRATES.”

“Mass Spectrometry represents the state-of-the art technology with a trend towards further expansion in the near future. It also meets most stringent quality criteria for routine diagnostics. We are pleased to start working with BIOCRATES which is highly experienced in the field of metabolomics and we are also happy to introduce this cutting edge technology to Turkish laboratories”, says Alper Söyler, General Manager of ONKOGEN.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BIOCRATES Test Kit Helps Develop First Metabolomics-Based Blood Test for Alzheimer’s
The test is capable of predicting, with 90% accuracy, the risk of Alzheimer’s disease 2–3 years before it has actually become clinically manifest.
Tuesday, March 18, 2014
BIOCRATES and Selexis Join Forces to Optimize High-yield Mammalian Cell Cultures
The agreement enables both the parties to combine their knowledge to help lower overall manufacturing costs for pharmacologically active proteins.
Tuesday, August 31, 2010
BIOCRATES Joins European Research Consortium – SysKid
The Company has joined a multi-partner European research program dedicated to improving the diagnosis and treatment of chronic kidney disease.
Thursday, April 01, 2010
BIOCRATES’ Metabolomics Expertise Provides New Insight into Functional Genomics
German researchers used Biocrates’ metabolomics expertise in research linking the genetic make-up of an individual to differences in their metabolism.
Tuesday, February 03, 2009
BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project
The latest framework six EU projects called COBRED will use technology platforms to find diagnostic biomarkers for two of the most common cancers, Colon and Breast Cancer.
Friday, May 11, 2007
Biocrates Raises €5 Million in Venture Financing
This investment further strengthens Biocrates’ position in the field of high content analysis and discovery of multiparametric biomarkers.
Thursday, June 29, 2006
Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
‘Big Data’ Drills Down Into Metabolic Details
Rice University bioengineers introduce efficient way to analyze, compare tissue-specific pathways.
New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
New Drug Delivery Method for Pancreatic Cancer
UCLA researchers use nanoparticles to send chemotherapy drug directly to the tumor site, reducing damage to healthy tissues.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!